ANL 28.52 Increased By ▲ 0.14 (0.49%)
ASC 16.71 Increased By ▲ 0.02 (0.12%)
ASL 23.75 Decreased By ▼ -0.11 (-0.46%)
AVN 94.24 Decreased By ▼ -0.65 (-0.69%)
BOP 9.47 Decreased By ▼ -0.02 (-0.21%)
BYCO 9.57 Decreased By ▼ -0.05 (-0.52%)
DGKC 110.51 Increased By ▲ 0.02 (0.02%)
EPCL 47.50 Decreased By ▼ -0.02 (-0.04%)
FCCL 21.15 Decreased By ▼ -0.15 (-0.7%)
FFBL 27.96 Increased By ▲ 0.08 (0.29%)
FFL 19.27 Decreased By ▼ -0.08 (-0.41%)
HASCOL 14.31 Decreased By ▼ -0.01 (-0.07%)
HUBC 86.00 Decreased By ▼ -0.14 (-0.16%)
HUMNL 7.26 Decreased By ▼ -0.03 (-0.41%)
JSCL 31.45 Decreased By ▼ -0.15 (-0.47%)
KAPCO 40.76 Decreased By ▼ -0.07 (-0.17%)
KEL 4.10 Decreased By ▼ -0.01 (-0.24%)
LOTCHEM 16.19 Increased By ▲ 0.03 (0.19%)
MLCF 43.05 Decreased By ▼ -0.16 (-0.37%)
PAEL 39.85 Increased By ▲ 0.01 (0.03%)
PIBTL 12.90 Decreased By ▼ -0.09 (-0.69%)
POWER 11.40 Decreased By ▼ -0.01 (-0.09%)
PPL 93.29 Decreased By ▼ -0.39 (-0.42%)
PRL 23.80 Decreased By ▼ -0.08 (-0.34%)
PTC 9.30 Decreased By ▼ -0.02 (-0.21%)
SILK 1.21 Decreased By ▼ -0.01 (-0.82%)
SNGP 44.34 Decreased By ▼ -0.14 (-0.31%)
TRG 108.48 Decreased By ▼ -1.23 (-1.12%)
UNITY 33.15 Increased By ▲ 0.04 (0.12%)
WTL 1.12 No Change ▼ 0.00 (0%)
BR100 4,856 Decreased By ▼ -9.94 (-0.2%)
BR30 24,724 Decreased By ▼ -96.85 (-0.39%)
KSE100 45,868 Decreased By ▼ -116.42 (-0.25%)
KSE30 19,061 Decreased By ▼ -87.18 (-0.46%)
World

India wants Pfizer to do local study for approval

  • As of now, the pre-condition for any vaccine to be implemented in India is that you have to do a bridging trial.
  • Paul also said Russia's Sputnik V, a shot undergoing last-stage trials in India, will soon apply for emergency-use approval in the country.
13 Jan 2021

NEW DELHI: Any vaccine maker, including Pfizer Inc, which has sought emergency-use authorisation for its COVID-19 shot in India, must conduct a local "bridging" safety and immunogenicity study to be considered for the country's immunisation programme, a senior government official told Reuters.

Serum Institute of India, the local manufacturer of the vaccine developed by AstraZeneca Plc and Oxford University, has done a similar study on more than 1,500 people over months before seeking and receiving emergency approval in the country.

Local media have reported that Pfizer had sought an exception when last month it became the first company to seek emergency-use approval in India for its vaccine already in use overseas. The company has not attended subsequent meetings called by India's drugs regulator.

"As of now, the pre-condition for any vaccine to be implemented in India is that you have to do a bridging trial," Vinod K. Paul, who heads a government panel on vaccine strategy, said in an interview in his office near the parliament building.

A Pfizer spokeswomen did not immediately respond to a request seeking comment.

Paul also said Russia's Sputnik V, a shot undergoing last-stage trials in India, will soon apply for emergency-use approval in the country.

No vaccine maker will be given indemnity by the government should something go wrong, Paul said. Serum Institute had written to the government seeking indemnity. AstraZeneca has said it has received such indemnity in many other countries.

India has also approved for emergency use a vaccine developed locally by Bharat Biotech.